Clinical trial · Expanded Access
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic), Confirmed Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF), for Whom Standard Systemic Therapy Has Failed or Progressed, in Whom There Are no Satisfactory Treatment Alternatives and Who Are Not Eligible for Other Clinical Trials.
NCT05941637CI-TRIAL-00084208no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Kidney cancer belongs to a heterogeneous group of tumors and is the most common oncourological disease; up to 80% of cases are clear cell carcinoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clear Cell Kidney Cancer | — | UNRESOLVED | — |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axitinib 5 MG | Drug | Axitinib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented metastatic renal cell cancer or cell kidney cancer * Evidence of measurable disease. * Adequate renal function (serum creatinine level) * ECOG Status 0-1 * Patient must provide signed informed consent * Male or female, age \>/= 18 years Exclusion Criteria: * Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors * Current use or anticipated need for treatment with drugs that are known as potent CYP3A4 or CYP1A2. * Active gastrointestinal bleeding. * Severe allergic reactions * Unwillingness or inability to comply with mandated pretreatment biopsy or therapeutic regimen
References
Publications (0)
Data not yet available
No reference posted for this study.